Project Grant R43HL139105

Federal Project Grant Award Summary Emprime Therapeutics Inc. received a $314,363 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of August 31, 2026. The award funds development of a novel dual adeno-associated virus (AAV) vector technology called STITCHR to enable full-length Factor VIII (FVIII) gene replacement therapy for hemophilia A. Current...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

Federal Project Grant Award Summary Haima Therapeutics LLC received a $944,676 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025, with a completion date of June 30, 2027. The award supports the development and advancement of Synthoplate (SP), a platelet-inspired synthetic hemostatic nanoparticle designed to restore hemostatic function in traumatic brain injury (TBI) patients...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $760,083 Project Grant to the University of Colorado-Denver on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the protein C system's role in trauma-induced coagulopathy (TIC) and thromboinflammation. The four-year research initiative, which extends through May 31, 2029, will investigate mechanistic pathways underlying trauma-related...

Federal Project Grant Award Summary Emory University received a $1.59M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded May 1, 2025, with completion targeted for January 31, 2029. The project delivers development and validation of an innovative diagnostic technology platform for detecting heparin-induced thrombocytopenia (HIT), a serious adverse drug reaction affecting 0.1%-5.0% of patients...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $234,750 project grant effective August 1, 2025, through July 31, 2027, under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports basic immunological research investigating anti-Factor VIII (FVIII) Immunoglobulin M (IgM) responses in hemophilia A patients. The research aims to identify immunologic mechanisms that initiate and orchestrate the formation...

Federal Project Grant Award Summary SNJ Pharma Inc. received a $499,882 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) on September 15, 2025, with a completion date of August 31, 2026. The grant funds the development and evaluation of a novel plasmin-independent thrombolytic agent called recombinant High-Temperature Requirement A1 (rHtra1) designed to treat pulmonary embolism (PE). This research...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant of $636,982 (awarded August 15, 2025, with completion targeted for May 31, 2030) under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports comprehensive research investigating the proteolytic regulation of Factor VIII (FVIII), a critical blood clotting protein, both before and after its activation....

This $8,042,749 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at The Ohio State University to enhance the safety and efficacy of low-titer Group O whole blood. The research involves determining optimal concentrations of hemopexin, haptoglobin, and transferrin to neutralize hemolytic byproducts during ex vivo storage of whole blood units. The project includes testing this protein...

Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $328,752 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The grant supports research investigating the role of coagulation factors—specifically tissue plasminogen activator (TPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway...